The Drug Quality and Security Act (DQSA) was enacted by Congress on November 27, 2013. Title 2 of the of the DQSA, the Drug Supply Chain Security Act (DSCSA) delineates steps to “achieve interoperable, electronic tracing of products at the package level to identify and trace certain prescription drugs as they are distributed in the United States.”
The DSCSA aids in safeguarding patients from exposure to counterfeit, stolen, contaminated or harmful drugs. Some DSCSA compliance requirements are already in play. The November 27, 2024 extended stabilization deadline is the second part of DSCSA, which addresses the Track and Trace serialization law, providing direction on how to track and trace transaction histories as prescription drugs move from pharmaceutical manufacturing sites to pharmacies.
Identify a product, which includes using unique barcode product identifiers, which are applied on drug packages and can be read electronically. All products must have the appropriate product identifiers that enable the product to be traced which entails GTIN (Global Trade Item Number) serial number, lot, and expiration dates.
Pharmacies are required to be interoperable to keep and receive serialized EPCIS (Electronic Product Code Information Services) product information for each prescription drug. This encompasses the ability to trace a product’s transfer of ownership through the secure exchange of transaction information.
Authorized trading partners (ATPs) need to be able to be identified electronically and products can only be purchased from authorized trading partners with valid licenses.
Validate the authenticity of suspect products with the manufacturer and inform trading partners.
Electronic Data Retention is required, ensuring the data is complete, accurate, and stored for 6 years.
DSCSA Standard Operating Procedures must be established to document the process to identify suspect drugs.
Licensure verification is required for all drug suppliers, maintaining DSCSA compliance between pharmacies and drug suppliers.
Using the FDA 3911 form, report suspect products at once.
Check for the inclusion of a package identifier (PI) to identify and the data (EPCIS) upon receipt and inform suppliers of any gaps.
